-- Kamada Rises to Six-Month High on Juvenile Diabetes Drug Trials
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-04-16T08:08:01Z
-- http://www.bloomberg.com/news/2012-04-16/kamada-rises-to-six-month-high-on-juvenile-diabetes-drug-trials.html
Kamada Ltd. (KMDA)  rose to the highest
level in almost six months after the biopharmaceutical company
said initial results from Phase I and II clinical trials on a
drug to treat juvenile diabetes showed a positive trend.  The  shares  advanced 3.8 percent to 24.19 shekels at 10:48
a.m. in Tel Aviv, the highest level since Oct. 27, giving the
Nes Ziona-based company a market value of 668 million shekels
($178 million).  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  